Recipharm boosts BFS capacity with strategic manufacturing investment
Recipharm, a global contract development and manufacturing organization (CDMO), today announced a multi-million investment in a new Blow-Fill-Seal (BFS) manufacturing line, expanding capacity to support customer programs from development through commercial supply. The investment builds on 50 years of BFS expertise and further strengthens Recipharm’s position in sterile drug product development and manufacturing.
The expanded capacity will support a broad range of ophthalmic product programs, backed by dedicated local execution teams and a global network of experts.
Greg Behar, CEO of Recipharm, said: “Customers need sterile manufacturing partners that can combine technical expertise, operational scale and reliable delivery. This investment expands Recipharm’s BFS capacity, strengthens our technical offering and positions Recipharm to meet growing customer demand with the speed, scale and quality required for today’s complex product programs.”
Recipharm’s BFS capabilities include pilot-scale manufacturing for feasibility studies and early-stage supply; clinical-scale manufacturing for small batches and stability studies; and proven high-volume commercial production. Together, these capabilities support customer programs as they progress toward commercial supply.
Recipharm provides BFS capabilities across biologics and small molecules, for ophthalmic application as well as vaccines. For products with more specific handling requirements, Recipharm offers specialized handling environments for oxygen- and temperature-sensitive formulations, including nitrogen atmosphere filling and temperature-controlled environments.
BFS technology delivers practical manufacturing and supply benefits. Its fully automated aseptic processing helps reduce contamination risk, while plastic containers simplify the supply chain through fewer components, no breakage risk and easier transport. Compared with traditional glass filling processes, BFS can also support lower cost of goods and a reduced carbon footprint.
For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.com
Total Page Views: 127
